Always in the best of spirits and with a very strong faith, Jamon Tavio King is facing a battle with a very rare leukemia […] ...

Precision DNA editing gene therapy achieves deep remissions in aggressive leukemia previously considered incurable.

Orphan drug designation is granted by the FDA for therapies treating rare disease affecting fewer than 200,000 patients in the U.S., and provides development incentives including extended market ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Imviva Biotech's CTD402 to accelerate the ...

Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has approved the company’s oncology drug, Nelarabine Injection, ...

CTD402, an allogeneic CAR T-cell therapy, is designed for immediate administration and targets relapsed/refractory T-ALL and ...

A new type of cancer cell that "warrants urgent investigation" has been discovered in childhood leukemia and could impact clinical care. Research into new or repurposed treatments that target this new ...

A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in ...

Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...